Market News & Trends
AIT Therapeutics Granted Orphan Drug Designation
AIT Therapeutics Inc. recently announced the US FDA has granted orphan drug designation to the company for its novel NO formulation for the treatment of…
KemPharm & Genco Sciences Announce Technology Licensing Agreement
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently announced it has entered into a technology licensing…
Achieve Life Science Announces Advancement of Cytisine Clinical Development Program
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, recently announced the commencement of…
Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, recently announced the completion of its Series E financing, raising $58 million. The Series E…
International Stem Cell Corporation to Expand its Revenue-Generating Biomedical Businesses to Support Ongoing & Future Clinical Trials
International Stem Cell Corporation recently announced that ISCO’s wholly owned subsidiaries Lifeline Cell Technology (LCT) and Lifeline Skin Care (LSC) expanded their manufacturing operations, OEM…
Aushon BioSystems & ABL, Inc. Announce Adoption of the Cira Platform
Aushon BioSystems and ABL, Inc. recently announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. Effective immediately, ABL will offer…
Intellia Therapeutics Demonstrates Sustained & Durable Genome Editing With CRISPR/Cas9 in 1-Year Animal Study
Intellia Therapeutics, Inc. recently presented the full 12-month data of its completed long-term mouse study, demonstrating robust and durable in vivo genome editing post single-dose,…
Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial
Ascendis Pharma A/S recently announced it has dosed subjects in a Phase 1 trial of TransCon PTH, a long-acting prodrug of parathyroid hormone (PTH) in…
ChromaDex Announces Top-line Results of its Second Human Clinical Trial
ChromaDex Corp. recently announced the initial results of its second human clinical study of NIAGEN nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably…
Amyris Enters Second Major Product Development & Production Agreement With Royal DSM
Amyris, Inc. recently announced it has entered into a product development and production agreement for Vitamin A with Koninklijke DSM N.V. (Royal DSM). This marks…
American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid & Useful for Clinicians Evaluating Obstructive CAD
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, recently announced today in a Scientific Statement by the American Heart Association, the Corus® CAD…
Q BioMed Announces Development Partnership With Sphaera Pharma
Q BioMed Inc. recently announced a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. "The…
ValGenesis Announces Strategic Partnership With VTI Life Sciences
ValGenesis Inc. recently announced the strategic partnership with VTI Life Sciences (VTI). This partnership enables VTI to provide clients with validation services using the latest…
Cytokinetics Announces Dosing of First Patient in Phase 3 Clinical Trial, Triggers $10-Million Milestone Payment
Cytokinetics, Incorporated recently announced that the first patient has been dosed in Japan in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility…
Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency & Antibody Drug Conjugate Commercial Facility
Ajinomoto Althea, Inc. recently announced it will soon open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility located…
Aclaris Therapeutics Announces Phase 2 Clinical Trial Data
Aclaris Therapeutics, Inc. recently announced that results from a Phase 2 clinical trial evaluating two concentrations (40% and 32.5%) of its drug candidate A-101 for…
ERT Reduces eCOA Delivery Time for Vaccine Trials by 75%
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, recently announced a technology platform that provides fast, regulatory compliant,…
Roivant Sciences Launches Datavant to Improve Clinical Trials With Artificial Intelligence
Roivant Sciences recently announced the launch of Datavant, a new company focused on employing artificial intelligence to improve the clinical trial process. Datavant will be…
Catalent to Acquire Cook Pharmica for $950 Million
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced it has…
Aptose Biosicences & CrystalGenomics Announce Issuance of US Patent
Aptose Biosciences Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,758,508 titled 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE…
